Aylin Ozkan

Aylin Ozkan


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2022 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
BGBUSRA GUREL
BUSRA GUREL
EÇEda Çapkın
Eda Çapkın
APAyhan Parlar
Ayhan Parlar
AOAylin Ozkan
Aylin Ozkan
MÇMeltem Çorbacıoğlu
Meltem Çorbacıoğlu
MYMeral Yüce
Meral Yüce
Bevacizumab is a humanized therapeutic monoclonal antibody used to reduce angiogenesis, a hallmark of cancer, by binding to VEGF-A. Many pharmaceutical companies have developed biosimilars of Bevacizumab in the last decade. The official reports provided by the FDA and EMA summarize the analytical performance of biosimilars as compared to the originators without giving detailed analytical procedures. In the current study, several key methods were optimized and reported for analytical and functional comparison of bevacizumab originators (Avastin, Altuzan) and approved commercial biosimilars (Zirabev and Mvasi). This case study presents a comparative analysis of a set of biosimilars under optimized analytical conditions for the first time in the literature. The chemical structure of all products was analyzed at intact protein and peptide levels by high-resolution mass spectrometry; the major glycoforms and posttranslational modifications, including oxidation, deamidation, N-terminal PyroGlu addition, and C-terminal Lys clipping, were compared. The SPR technique was used to reveal antigen and some receptor binding kinetics of all products, and the ELISA technique was used for C1q binding affinity analysis. Finally, the inhibition performance of the samples was evaluated by an MTS-based proliferation assay in vitro. Major glycoforms were similar, with minor differences among the samples. Posttranslational modifications, except C-terminal Lys, were determined similarly, while unclipped Lys percentage was higher in Zirabev. The binding kinetics for VEGF, FcRn, FcγRIa, and C1q were similar or in the value range of originators. The anti-proliferative effect of Zirabev was slightly higher than the originators and Mvasi. The analysis of biosimilars under the same conditions could provide a new aspect to the literature in terms of the applied analytical techniques. Further studies in this field would be helpful to better understand the inter-comparability of the biosimilars.

28 July 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
BGBUSRA GUREL
BUSRA GUREL
MBMelike Berksöz
Melike Berksöz
ECEda Capkin
Eda Capkin
APAyhan Parlar
Ayhan Parlar
MPMeltem Corbacioglu Pala
Meltem Corbacioglu Pala
MYMeral Yüce
Meral Yüce
Avastin® is a humanized recombinant monoclonal antibody used to treat cancer by targeting VEGF-A to inhibit angiogenesis. SIMAB054, an Avastin® biosimilar candidate developed in this study, showed a different charge variant profile than its innovator. Thus, it is fractionated into acidic, main, and basic isoforms and collected physically by Cation Exchange Chromatography (CEX) for a comprehensive structural and functional analysis. The innovator product, fractionated into the same species and collected by the same method, is used as a reference for comparative analysis. Ultra-Performance Liquid Chromatography (UPLC) ESI-QToF was used to analyze the modifications leading to charge heterogeneities at intact protein and peptide levels. The C-terminal lysine clipping and glycosylation profiles of the samples were monitored by intact mAb analysis. The post-translational modifications, including oxidation, deamidation, and N-terminal pyroglutamic acid formation, were determined by peptide mapping analysis in the selected signal peptides. The relative binding affinities of the fractionated charge isoforms against the antigen, VEGF-A, and the neonatal receptor, FcRn, were revealed by Surface Plasmon Resonance (SPR) studies. The results show that all CEX fractions from the innovator product and the SIMAB054 shared the same structural variants, albeit in different ratios. Common glycoforms and post-translational modifications were the same, but at different percentages for some samples. The dissimilarities were mostly originating from the presence of extra C-term Lysin residues, which are prone to enzymatic degradation in the body, and thus they were previously assessed as clinically irrelevant. Another critical finding was the presence of different glyco proteoforms in different charge species, such as increased galactosylation in the acidic and afucosylation in the basic species. SPR characterization of the isolated charge variants further confirmed that basic species found in the CEX analyses of the biosimilar candidate were also present in the innovator product, although at lower amounts. The charge variants’ in vitro antigen- and neonatal receptor-binding activities varied amongst the samples, which could be further investigated in vivo with a larger sample set to reveal the impact on the pharmacokinetics of drug candidates. Minor structural differences may explain antigen-binding differences in the isolated charge variants, which is a key parameter in a comparability exercise. Consequently, such a biosimilar candidate may not comply with high regulatory standards unless the binding differences observed are justified and demonstrated not to have any clinical impact.

21 March 2025 in Turkish Journal of Biochemistry
Verified
Journal Article
Open access
PDF file
ESElif Sahinkaya
Elif Sahinkaya
AOAylin Ozkan
Aylin Ozkan
NONilay Ozdemir
Nilay Ozdemir
MAMerve Elif Aslan
Merve Elif Aslan
DBDilan Bicak
Dilan Bicak
EYEce Kok Yetimoglu
Ece Kok Yetimoglu
Objectives: After reviewing the reference product specifications, found that they include the SEC HPLC result but do not specify Protein A chromatography as a test. Although there is no record of reference product specifications, alternative methods are necessary, particularly for routine analysis of biotechnological products. Methods: The SEC mobile phase consisted of 0.1 M sodium phosphate and 0.2 M saline buffer pH 6.80 run isocratically at a flow rate of 0.5 mL/min. The Protein A chromatography column was equilibrated (60 mM sodium phosphate buffer, pH 7.4 (binding buffer), 60 mM sodium phosphate buffer, pH 2.5 (elution buffer) gradient system) at 1 mL/min. Results: The SEC HPLC method validation study was conducted, ranging from (0.01–2.0 mg/mL) 1.0 % (LLOQ level) to 200 %. The Protein A chromatography method between (0.0078 and 4.0 mg/mL) 0.78 % (LLOQ level) and 400 % linearity levels. In the linearity study, both ANOVA and Graphpad results were shown. Both bioanalytical methods were performed by establishing validation parameters for the mAb reference product in accordance with the ICH M10 guideline. Conclusions: Additionally, the findings shed light on routine titer analysis of biotechnological products, as there is no documentation in the literature regarding Protein A chromatography validation.